DOCMORRIS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.38 CHF | 0.00% |
|
0.00% | 0.00% |
| Jul. 12 | DOCMORRIS : Hauck & Aufhauser reaffirms its Buy rating | ZD |
| Jul. 12 | DOCMORRIS : Deutsche Bank reiterates its Buy rating | ZD |
| Sales 2024 * | 1.15B 1.29B | Sales 2025 * | 1.52B 1.69B | Capitalization | 609M 681M |
|---|---|---|---|---|---|
| Net income 2024 * | -87M -97.16M | Net income 2025 * | -32M -35.74M | EV / Sales 2024 * | 0.74 x |
| Net Debt 2024 * | 248M 277M | Net Debt 2025 * | 285M 319M | EV / Sales 2025 * | 0.59 x |
| P/E ratio 2024 * |
-6.67
x | P/E ratio 2025 * |
-21.8
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on DocMorris AG
More press releases
More news
| 1 day | -47.60% |
| Managers | Title | Age | Since |
|---|---|---|---|
Walter Hess
CEO | Chief Executive Officer | 59 | 14-12-31 |
| Founder | 66 | 93-04-05 | |
Marcel Ziwica
DFI | Director of Finance/CFO | 49 | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 10-03-31 | |
Florian Seubert
BRD | Director/Board Member | 51 | 19-05-22 |
| Founder | 66 | 93-04-05 |
Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.
Sector
Drug Retailers
Calendar
2024-08-20
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
47.3
CHF
Average target price
91.83
CHF
Spread / Average Target
+94.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.19% | 10.1B | |
| -46.55% | 8.81B | |
| -25.71% | 6.65B | |
| -4.16% | 6.45B | |
| +97.00% | 5.35B | |
| -3.07% | 4.63B | |
| +8.08% | 4.6B | |
| -32.12% | 3.79B | |
| +6.91% | 3.13B |
- Stock Market
- Equities
- ROSE Stock
- ROSE Stock
